Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Rafael Holdings, Inc. (RFL : NYSE)

• Company Description    Rafael Holdings Inc. manufactures metabolic oncology drugs to treat cancer. The company's product pipeline consists of CPI-613, CPI-618, CPI-1826 and CPI-3220 which are in clinical stages. Rafael Holdings Inc. is based in Newark, United States. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $1.23 Daily Weekly Monthly 20 Day Moving Average: 149,434 shares Shares Outstanding: 51.77 (millions) Market Capitalization: $63.68 (millions) Beta: 0.69 52 Week High: $3.19 52 Week Low: $1.17 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.82% -1.31% 12 Week -18.54% -20.01% Year To Date -25.45% -35.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 520 BROAD STREET - NEWARK,NJ 07102 USA ph: 212-658-1450 fax: - invest@rafaelholdings.com http://www.rafaelholdings.com

• General Corporate Information    Officers Howard Jonas - Chief Executive Officer Joshua Fine - Chief Operating Officer David Polinsky - Chief Financial Officer Alan Grayson - Director Markus W. Sieger - Director Peer Information Rafael Holdings, Inc. (GSAC) Rafael Holdings, Inc. (CASI) Rafael Holdings, Inc. (ALCD.) Rafael Holdings, Inc. (OMNN) Rafael Holdings, Inc. (CGPI.) Rafael Holdings, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 75062E106 SIC: 2834 Fiscal Year Fiscal Year End: July Last Reported Quarter: 10/01/25 Next Expected EPS Date: 03/12/26 Share - Related Items Shares Outstanding: 51.77 Most Recent Split Date: (:1) Beta: 0.69 Market Capitalization: $63.68 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.71 Price/Cash Flow: - Price / Sales: 61.88 EPS Growth vs. Year Ago Period: 48.65% vs. Previous Quarter: 32.14% Sales Growth vs. Year Ago Period: 87.50% vs. Previous Quarter: -31.43% ROE 10/31/25 - -32.82 07/31/25 - -33.01 04/30/25 - -24.75 ROA 10/31/25 - -27.55 07/31/25 - -27.95 04/30/25 - -21.12 Current Ratio 10/31/25 - 4.00 07/31/25 - 4.89 04/30/25 - 3.85 Quick Ratio 10/31/25 - - 07/31/25 - 4.86 04/30/25 - 3.82 Operating Margin 10/31/25 - -2,748.30 07/31/25 - -2,995.64 04/30/25 - -2,710.93 Net Margin 10/31/25 - -3,044.70 07/31/25 - -3,328.24 04/30/25 - -3,127.60 Pre-Tax Margin 10/31/25 - -3,283.19 07/31/25 - -3,620.06 04/30/25 - -3,539.48 Book Value 10/31/25 - 1.72 07/31/25 - 1.91 04/30/25 - 2.64 Inventory Turnover 10/31/25 - 0.50 07/31/25 - 0.94 04/30/25 - 2.56 Debt-to-Equity 10/31/25 - 0.00 07/31/25 - 0.00 04/30/25 - 0.00 Debt-to-Capital 10/31/25 - 0.06 07/31/25 - 0.08 04/30/25 - 0.09

Powered by Zacks Investment Research ©